Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

EASD 2026 28 September - 2 October 2026

Impact of cagrilintide 2.4 mg on physical function – post hoc patient-reported outcomes from REDEFINE 1​

Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.
Keywords
Obesity
Congress short oral presentation
Amylin
CagriSema
PHASE 3 (RCT)